| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Institute of Pathology [I-M. S., T. G. P., R. B. P., T. P. P.], Department of Molecular Biology and Microbiology [D. R. R., H-J. K.], and Department of Genetics [S. S.], Case Western Reserve University, Cleveland, Ohio 44106
| ABSTRACT |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
DNA Preparation.
DNA was isolated from serial paraffin sections in the following manner. The slides of the ACF were deparaffinized through xylenes and decreasing alcohols into water, stained for 2 min with hematoxylin or 1% methyl green, and stored in distilled water for 2060 min before being dissected. Using a 1-µm needle (Fisher Scientific, Pittsburgh, PA), approximately five to eight crypts from six to eight sections of each ACF were scraped into 20 µl of digestion buffer [50 mM Tris (pH 8.5), 0.5% Tween 20, and 200 µg/ml proteinase K (Sigma, St. Louis, MO)] and incubated at 55°C for 3 h (10)
. Samples of normal colonic tissue that included stromal, muscle, and epithelial cells were scraped from the same slides as used for the ACF. Another set of six to eight sections was used for the microdissection of epithelial cells from five to eight normal crypts and their adjacent normal colonic tissue. An example of a microdissection of crypts is shown in Fig. 1
. Proteinase K was inactivated with phenylmethylsulfonyl fluoride (Boehringer Mannheim, Indianapolis, IN) at a final concentration of 100 mM (11)
. This DNA solution (910 µl) was either mock-digested with the digestion buffer and no enzyme or digested with 60 units of HpaII (40 units/ml; Boehringer Mannheim) in a total volume of 15 µl overnight at 37°C.
|
-33P]ATP. The end-labeling reaction was performed by incubating the following mixture at 37°C for 3060 min: 5 µl (20 µM) primer; 5 µl of 5x labeling buffer (Life Technologies, Inc.); 5 µl of [
-33P]ATP (10µCi/µl; 4000 Ci/mmol; Amersham, Arlington Heights, IL); 1 µl of T4 polynucleotide kinase (Life Technologies, Inc.); and 9 µl of distilled H2O for a total volume of 25 µl. After an initial denaturation of the PCR reaction mixture at 95°C for 2 min, 1.25 units of Taq (Qiagen) in 1 x PCR buffer (Qiagen) were added to the samples as a hot start. The samples were amplified for 35 cycles (PTC-100 thermocycler; MJ Research, Watertown, MA) under the following conditions (which were modified from Ref. 7
): 15 s at 95°C; 30 s at 60°C; and 30 s at 72°C.
Analysis of Clonality.
Amplified DNA (6 µl) was added to 4 µl of 40% formamide loading buffer; 3 µl of this mixture were loaded onto a 6% polyacrylamide gel and run at 55 W for 1.53 h. The gel was fixed for 1015 min in 5% acetic acid and 10% methanol, dried, and exposed to X-ray film (Fuji X-OMAT; Fisher Scientific) and a Kodak TranScreen LE intensifying screen (Eastman Kodak, New Haven, CT) at -70°C for 1921 h. Densitometry readings were performed on the autoradiograms with the 420 oe scanner (42 x 42-µm resolution with a white filter and an absorbance setting of 3.0) and QS30 software, version 2.5 (PDI, Huntington, NY). Each lane was read separately, and the intensities of the bands in each lane were measured as a percentage of the total intensity of the entire lane delimited. Ratios were then calculated in the following manner (8)
. The RAA for each sample before digestion with HpaII was calculated by dividing the relative percentage reading of the high molecular weight band by the relative percentage reading of the low molecular weight band; a ratio equal to 1 would demonstrate equal amplification of both alleles. For an experiment to be included, the RAA had to be equal to or greater than 0.6. The RAI(N) and RAI(E) were calculated by first obtaining the ratios of the high and low molecular weight bands for the (a) undigested samples and (b) the same samples after digestion with HpaII. Next, these ratios (a and b) were divided such that the larger ratio was the denominator, i.e., RAI(N) or RAI(E) < 1. The RAI(N) for the normal tissue had to be near 1 to allow the results from the corresponding experimental tissues to be included in the study. If RAI(E) < 0.4, the sample was considered monoclonal; if RAI(E) > 0.4, the sample was considered polyclonal (8)
.
| Results |
|---|
|
|
|---|
PCR studies were carried out on 22 ACF from 14 patients; four ACF from two patients were eliminated because the androgen receptor alleles from these patients appeared to be homozygous, i.e., were noninformative. This left 18 ACF from 12 female patients to be analyzed for clonality in this study. PCR amplification of the DNA from both the normal tissue and the ACF before and after digestion with HpaII was successful for 11 (Table 1
; Fig. 2
) of the 18 ACF. The RAA of the high molecular weight allele to the low molecular weight allele for normal colonic tissue, which includes stromal cells and epithelial cells, ranged between 0.65 and 1.39, with a mean of 0.90 ± 0.20 (± SD; Table 1
); this indicated approximately equal amplification of both androgen receptor alleles in each normal tissue sample analyzed for each patient, with a slight overamplification of the lower molecular weight allele as reported previously (8)
. The RAI(N) of this same tissue was close to 1 (0.81 ± 0.11, mean ± SD); this indicated approximate random inactivation of X chromosomes in the normal tissues analyzed. Duplicate analyses of each of the 11 ACF indicated a monoclonal population in all 11 ACF because the RAI(E) was < 0.4 (Table 1)
. The ACF ranged in size from 25 crypts to 225 crypts, included 7 ACF with mild dysplasia and 4 ACF with only atypia, and were located throughout the colon (5 ACF from the ascending colon, 1 ACF from the transverse colon, and 5 ACF from the distal colon). Two different ACF from patient 1429 showed inactivation of different androgen receptor alleles, whereas two ACF from patient 1900 showed inactivation of the same allele (Fig. 2)
. Epithelial cells that were microdissected from five to eight adjacent normal crypts from the same patients demonstrated polyclonal populations in seven of the eight patients (Table 2
; Fig. 2
). Two groups of eight normal crypts from two different locations from patient 1897 indicated monoclonal populations of cells with the same allele inactivated in each group of normal crypts. The monoclonal population of cells observed in the ACF from patient 1897, however, had the other allele inactivated (data not shown).
|
|
|
| Discussion |
|---|
|
|
|---|
Normal crypts in both mice (13) and humans (14) are monoclonal populations that arise from single stem cells, whereas patches of 6 10 normal crypts are polyclonal populations (15) . Because patches of one to four crypts appear to be monoclonal in normal mouse colon (15) , at least five crypts from each ACF were microdissected. An equivalent number of normal crypts from each patient were microdissected and analyzed by the PCR assay. In seven of the eight patients in this study, microdissection of equivalent numbers of adjacent normal crypts from the normal mucosa and aberrant crypts within an ACF led to patterns of random X inactivation in normal crypts and nonrandom X inactivation in ACF. The normal crypts microdissected from one patient exhibited a nonrandom pattern of X inactivation. However, the pattern of X inactivation of the eight normal crypts from two different locations was similar but differed from that of the ACF from this patient. These results are consistent with monoclonality of the ACF in a manner similar to that reported for a tumor specimen by Mashal et al. (7) .
With antibodies to detect H-2 antigens as markers of parental origin and cellular genotype, dysplastic foci in the colons of mice treated with a colon-specific carcinogen were shown to be monoclonal (16) . Human colorectal cancers have been demonstrated to be monoclonal (6) , although there are reports that some colonic adenomas in both humans (17 , 18) and mice (19) are polyclonal in origin. All of the reports of polyclonality in some colon tumors are from studies with humans or mice that inherited a mutant copy of the APC gene and thus may not be applicable to sporadic colon cancer. The presence of polyclonality in these colon tumors that arise in a background of an inherited mutant APC allele may be evidence for a dominant effect of the mutation as suggested by others (20) .
The finding of heterozygosity for the androgen receptor in 12 of 14 (87%) patients from whom ACF were analyzed is in the expected range for this assay (7) . A total of 7 of the 18 (39%) ACF that were informative with the androgen receptor assay were eliminated from this study because of persistently inconclusive and/or uninterpretable results. Lucas et al. (8) had unsuccessful results from 4 of 12 (33%) cases, and Mashal et al. (7) found skewing of the band intensities from normal tissues after digestion with HhaI in 3 of 13 (23%) cases; they discuss various reasons for this skewing, including nonrandom inactivation of the X chromosome. Mashal et al. (7) comment that "not all samples produced efficient amplification of DNA if the Chelex step was eliminated." Because our samples of DNA (even those from multiple sections of ACF) contained less DNA than those from the single 10-µm sections used by Mashal et al. (7) , we were unable to carry out the recommended purification with Chelex. The inconclusive results for seven ACF are most likely due to technical problems that may include overfixation of the tissue, loss of the tissue sample during microdissection, the presence of contaminants in the tissue, or incomplete digestion by the restriction enzyme HpaII. In addition, DNA extracted from archival paraffin blocks tends to be partially degraded as well as contaminated by blood or metals; this frequently leads to biased amplification of alleles and even a variation in the relative intensity of human androgen receptor products from different analyses of the same DNA samples (21) .
Our finding of monoclonality in ACF, including those without dysplasia, puts ACF at the earliest identified stage of neoplasia in the colon. Additional studies with larger sample sizes of ACF are needed to conclusively prove this hypothesis.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
1 Supported in part by NIH Grants CA66725, CA43703, and CA54031. ![]()
2 To whom requests for reprints should be addressed, at Institute of Pathology, Case Western Reserve University Medical Center, 2085 Adelbert Road, Cleveland, OH 44106. ![]()
3 The abbreviations used are: ACF, aberrant crypt foci; RAA, allele amplification ratio; RAI(N), allele inactivation ratio for the normal tissue; RAI(E), allele inactivation ratio for the experimental tissue. ![]()
Received 9/30/98. Accepted 11/ 5/98.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. G. Stevens, T. P. Pretlow, D. P. Hurlstone, C. Giardina, and D. W. Rosenberg Comment re: "Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention" and "Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial" Cancer Prevention Research, August 1, 2008; 1(3): 215 - 216. [Full Text] [PDF] |
||||
![]() |
O. K. Glebov, L. M. Rodriguez, P. Soballe, J. DeNobile, J. Cliatt, K. Nakahara, and I. R. Kirsch Gene Expression Patterns Distinguish Colonoscopically Isolated Human Aberrant Crypt Foci from Normal Colonic Mucosa. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2253 - 2262. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cohen, R. Mustafi, A. Chumsangsri, N. Little, J. Nathanson, S. Cerda, S. Jagadeeswaran, U. Dougherty, L. Joseph, J. Hart, et al. Epidermal Growth Factor Receptor Signaling Is Up-regulated in Human Colonic Aberrant Crypt Foci Cancer Res., June 1, 2006; 66(11): 5656 - 5664. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Luo, G.-Q. Shen, K. A. Stiffler, Q. K. Wang, T. G. Pretlow, and T. P. Pretlow Loss of heterozygosity in human aberrant crypt foci (ACF), a putative precursor of colon cancer Carcinogenesis, June 1, 2006; 27(6): 1153 - 1159. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Volate, D. M. Davenport, S. J. Muga, and M. J. Wargovich Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin) Carcinogenesis, August 1, 2005; 26(8): 1450 - 1456. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hulit, C. Wang, Z. Li, C. Albanese, M. Rao, D. Di Vizio, S. Shah, S. W. Byers, R. Mahmood, L. H. Augenlicht, et al. Cyclin D1 Genetic Heterozygosity Regulates Colonic Epithelial Cell Differentiation and Tumor Number in ApcMin Mice Mol. Cell. Biol., September 1, 2004; 24(17): 7598 - 7611. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Brittan and N A Wright STEM CELL IN GASTROINTESTINAL STRUCTURE AND NEOPLASTIC DEVELOPMENT Gut, June 1, 2004; 53(6): 899 - 910. [Full Text] [PDF] |
||||
![]() |
L.-C. Chen, C.-Y. Hao, Y. S. Y. Chiu, P. Wong, J. S. Melnick, M. Brotman, J. Moretto, F. Mendes, A. P. Smith, J. L. Bennington, et al. Alteration of Gene Expression in Normal-Appearing Colon Mucosa of APCmin Mice and Human Cancer Patients Cancer Res., May 15, 2004; 64(10): 3694 - 3700. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Pretlow, W. Edelmann, R. Kucherlapati, T. G. Pretlow, and L. H. Augenlicht Spontaneous Aberrant Crypt Foci in Apc1638N Mice with a Mutant Apc Allele Am. J. Pathol., November 1, 2003; 163(5): 1757 - 1763. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Luo, B. Li, and T. P. Pretlow DNA Alterations in Human Aberrant Crypt Foci and Colon Cancers by Random Primed Polymerase Chain Reaction Cancer Res., October 1, 2003; 63(19): 6166 - 6169. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li, L. Myeroff, D. Smiraglia, M. F. Romero, T. P. Pretlow, L. Kasturi, J. Lutterbaugh, R. M. Rerko, G. Casey, J.-P. Issa, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers PNAS, July 8, 2003; 100(14): 8412 - 8417. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Preston, W.-M. Wong, A. O.-O. Chan, R. Poulsom, R. Jeffery, R. A. Goodlad, N. Mandir, G. Elia, M. Novelli, W. F. Bodmer, et al. Bottom-up Histogenesis of Colorectal Adenomas: Origin in the Monocryptal Adenoma and Initial Expansion by Crypt Fission Cancer Res., July 1, 2003; 63(13): 3819 - 3825. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Wali, S. Khare, M. Tretiakova, G. Cohen, L. Nguyen, J. Hart, J. Wang, M. Wen, A. Ramaswamy, L. Joseph, et al. Ursodeoxycholic Acid and F6-D3 Inhibit Aberrant Crypt Proliferation in the Rat Azoxymethane Model of Colon Cancer: Roles of Cyclin D1 and E-Cadherin Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1653 - 1662. [Abstract] [Full Text] [PDF] |
||||
![]() |
N A Wright and R Poulsom Top down or bottom up? Competing management structures in the morphogenesis of colorectal neoplasms Gut, September 1, 2002; 51(3): 306 - 308. [Full Text] |
||||
![]() |
R G Hardy, C Tselepis, J Hoyland, Y Wallis, T P Pretlow, I Talbot, D S A Sanders, G Matthews, D Morton, and J A Z Jankowski Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon Gut, April 1, 2002; 50(4): 513 - 519. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Velcich, W. Yang, J. Heyer, A. Fragale, C. Nicholas, S. Viani, R. Kucherlapati, M. Lipkin, K. Yang, and L. Augenlicht Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2 Science, March 1, 2002; 295(5560): 1726 - 1729. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hartmann, G. Schlake, D. Zaak, E. Hungerhuber, A. Hofstetter, F. Hofstaedter, and R. Knuechel Occurrence of Chromosome 9 and p53 Alterations in Multifocal Dysplasia and Carcinoma in Situ of Human Urinary Bladder Cancer Res., February 1, 2002; 62(3): 809 - 818. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. P. Hao, T. G. Pretlow, J. S. Rao, and T. P. Pretlow {beta}-Catenin Expression Is Altered in Human Colonic Aberrant Crypt Foci Cancer Res., November 1, 2001; 61(22): 8085 - 8088. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Pretlow, R. P. Bird, Y. Yamada, Y. Hirose, A. Hara, and H. Mori Correspondence re: Y. Yamada et al., Frequent {beta}-Catenin Gene Mutations and Accumulations of the Protein in the Putative Preneoplastic Lesions Lacking Macroscopic Aberrant Crypt Foci Appearance, In Rat Colon Carcinogenesis. Cancer Res., 60: 3323-3327, 2000; and Sequential Analysis of Morphological and Biological Properties of {beta}-Catenin-accumulated Crypts, Provable Premalignant Lesions Independent of Aberrant Crypt Foci in Rat Colon Carcinogenesis. Cancer Res., 61: 1874-1878, 2001. Cancer Res., October 1, 2001; 61(20): 7699 - 7701. [Full Text] [PDF] |
||||
![]() |
M. Pedroni, E. Sala, A. Scarselli, F. Borghi, M. Menigatti, P. Benatti, A. Percesepe, G. Rossi, M. Foroni, L. Losi, et al. Microsatellite Instability and Mismatch-Repair Protein Expression in Hereditary and Sporadic Colorectal Carcinogenesis Cancer Res., February 1, 2001; 61(3): 896 - 899. [Abstract] [Full Text] |
||||
![]() |
X. P. Hao, T. G. Pretlow, J. S. Rao, and T. P. Pretlow Inducible Nitric Oxide Synthase (iNOS) Is Expressed Similarly in Multiple Aberrant Crypt Foci and Colorectal Tumors from the Same Patients Cancer Res., January 1, 2001; 61(2): 419 - 422. [Abstract] [Full Text] |
||||
![]() |
M. J. Wargovich, A. Jimenez, K. McKee, V. E. Steele, M. Velasco, J. Woods, R. Price, K. Gray, and G. J. Kelloff Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression Carcinogenesis, June 1, 2000; 21(6): 1149 - 1155. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Jang and L. Mao Methylation Patterns in Human Androgen Receptor Gene and Clonality Analysis Cancer Res., February 1, 2000; 60(4): 864 - 866. [Abstract] [Full Text] |
||||
![]() |
X. P. Hao, J. E. Willis, T. G. Pretlow, J. S. Rao, G. T. MacLennan, I. C. Talbot, and T. P. Pretlow Loss of Fragile Histidine Triad Expression in Colorectal Carcinomas and Premalignant Lesions Cancer Res., January 1, 2000; 60(1): 18 - 21. [Abstract] [Full Text] |
||||
![]() |
C. M. Fenoglio-Preiser and A. Noffsinger Review Article: Aberrant Crypt Foci: A Review Toxicol Pathol, November 1, 1999; 27(6): 632 - 642. [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |